-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Ascendis Pharma, Lowers Price Target to $326

Benzinga·08/31/2026 17:15:44
Listen to the news
Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $328 to $326.